When a clinical trial runs behind schedule, consequences are often measured by timelines, budgets, and missed milestones. But, there is another key metric that the industry rarely quantifies: lost time for patients waiting for new therapies. For many, time is not something they can afford to lose.
Without the tools and technology to monitor the study in real time, workflows break, progress stalls, and studies are compromised.
And when that happens, patients ultimately pay the biggest price.
Why Traditional Oversight is Stalling Clinical Trials
Clinical trial oversight was designed for a different era.
Today trials involve more patients, more sites, and more complex protocols than ever, generating enormous amounts of operational and clinical data.
Maintaining the integrity of that data is essential for regulators who evaluate whether a therapy should reach the market. Yet the teams responsible for managing this complexity often operate across fragmented systems and organizational silos. Small issues become harder to detect — and often compound before they can be corrected.
And because of traditional oversight, delays in trials have almost become expected — which can be detrimental for patients.
Research shows nearly 80% of clinical trials fail to meet their original enrollment timelines. Protocol deviations are one of the most common causes, particularly in complex global studies where operations teams are tasked with overseeing multiple sites and on-site teams are stretched thin. In these conditions, human error becomes unavoidable.
One common risk occurs when patients are enrolled in studies for which they are not eligible. In small numbers, eligibility deviations may not jeopardize a trial. When identified early, these issues can often be corrected by replacing the affected patient — which can be disappointing in itself.
However, in large numbers, the consequences become more serious. Large numbers of ineligible patients may need to be replaced in order to pass inspection. If the issue is caught too late, the trial may not be completed on time. If not caught at all, the trial may fail.
For patients already participating, and for those waiting for the therapy being studied, this means more disappointment — and more time without a potential solution.
How Operational Oversight Innovation Matters for Patients
Every trial that falls behind schedule affects the speed at which new therapies can reach patients. The impact is felt across the entire clinical ecosystem trying to do right by people in need — from study managers overseeing the day-to-day execution, the CRO partners responsible for delivery, and the Chief Medical Officer accountable for timelines, costs, and the trial’s success.
With the growing breadth and complexity of clinical trial data, operational oversight can no longer just be a monitoring function — it needs to be a strategic capability that connects every level of a trial.
Leveraging modernized oversight solutions allows organizations to detect risk earlier, act with greater confidence, and keep trials on track — ultimately delivering on the promise of bringing new therapies to patients faster.
Achieving this requires a shift from traditional monitoring to real-time operational intelligence.
Connecting Oversight to Real-Time Action
Instead of relying on retrospective monitoring, new operational intelligence platforms like espresso enable clinical leaders to see how trials are performing while they are still in motion, turning fragmented operational signals into actionable insight for study teams.
This shift — from fragmented oversight to connected operational intelligence — has the potential to fundamentally change how clinical trials are managed.
Not just to protect timelines or budgets.
But to ensure that operational complexity never becomes the reason patients wait longer for the therapies they need.
Drug development already takes 10-15 years on average. The real question is how much of that time is unavoidable — and how much is the result of operational blind spots that keep patients waiting longer than they should.
As clinical trials generate more data than ever before, the challenge is no longer collecting information — it’s turning operational signals into timely action.
1. Brøgger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis. J Med Internet Res. 2020;22(11):e22179. Published 2020 Nov 4. doi:10.2196/22179
2. Chodankar D. Impact of protocol deviations on the clinical study. Perspect Clin Res. 2023;14(2):47-48. doi:10.4103/picr.picr_69_23
